BRISTOL-MYERS SQUIBB COMPANY Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent of $15.00 million as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent · last filed 2026-02-11
- 2025-12-31: Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent $15.00M.
- 2025-09-30: Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent $16.00M.
- 2025-06-30: Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent $200.00M.
- 2025-03-31: Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent $220.00M.
| Period end | Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent |
|---|---|
| 2025-12-31 | $15.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $16.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $200.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $220.00M 10-Q · filed 2025-04-24 |
| 2024-12-31 | $452.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $422.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $642.00M 10-Q · filed 2024-07-26 |
| 2024-03-31 | $659.00M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $436.00M 10-K · filed 2025-02-12 |
| 2023-09-30 | $432.00M 10-Q · filed 2023-10-26 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |